Immunoglobulin G4-related hypertrophic pachymeningitis: A case-oriented review

Published on Jul 1, 2019in Neuroimmunology and Neuroinflammation
· DOI :10.1212/NXI.0000000000000568
M. Levraut1
Estimated H-index: 1
Mikael Cohen10
Estimated H-index: 10
+ 8 AuthorsChristine Lebrun-Frenay17
Estimated H-index: 17
Objective Meningeal involvement in Immunoglobulin G (IgG)-4-related disease is rare and only described in case reports and series. Because a review into the disease is lacking, we present 2 cases followed by a literature review of IgG4-related hypertrophic pachymeningitis (IgG4-HP). Methods Two IgG4-HP cases were reported, one involving the spinal cord and responding to surgical management and a second involving the brain and responding to Rituximab therapy. We then review clinical cases and case-series of histologically proven IgG4-HP that were published in the PubMed-NCBI database. Results Forty-two case reports and 5 case-series were studied (60 patients, 20 women). The median age was 53. Eighteen patients had systemic involvement and 24 had single-organ IgG4-HP. Fifty-five percent of patients had an elevated serum IgG4. Treatment was surgical in 20/53 cases. Steroid therapy and immunosuppressors were effective in 85% and more than 90% of the cases, respectively. The rate of disease relapse was 42.1% after steroid therapy was discontinued. Discussion/conclusion IgG4-HP is characterized by the lack of extra-neurologic organ-involvement and systemic signs. Histopathologic studies should be performed as it is crucial for diagnosis because serum markers are rarely informative. 18F-FDG positon tomography can be useful to characterize systemic forms. There is no specific CSF marker for IgG4-HP and the diagnostic value of CSF IgG4 levels needs to be studied with larger samples. We provide a treatment algorithm for IgG4-HP. Such treatment strategies rely on early surgery, steroids, and early immunosuppressive therapy to prevent neurologic complications.
Figures & Tables
  • References (33)
  • Citations (0)
📖 Papers frequently viewed together
1 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
Intrathecal administration of rituximab—an anti-CD20 monoclonal antibody—is emerging as a promising therapeutic strategy for B cell lymphomas of the central nervous system (CNS).1 2 The rationale for administering rituximab directly into the cerebrospinal fluid (CSF) stems from the need to achieve optimal therapeutic concentrations within the intrathecal compartment. Rituximab, in fact, has a high molecular weight and only 0.1%–0.5% of its plasmatic concentrations crosses the ‘blood-brain barrie...
9 CitationsSource
#1Mahmoud A. AbdelRazek (Harvard University)H-Index: 1
#2Nagagopal Venna (Harvard University)H-Index: 16
Last. John H. Stone (Harvard University)H-Index: 70
view all 3 authors...
Summary IgG4-related disease can involve nearly any organ system, including the central and peripheral nervous systems. The pathology findings are consistent from organ to organ, but careful clinicopathological correlation is necessary to establish the diagnosis. Many non-neurological and neurological inflammatory conditions, previously regarded as idiopathic in nature, are now recognised to fall within the spectrum of IgG4-related disease. The condition is highly treatable, but probably remains...
11 CitationsSource
Last. Benjamin Terrier (Paris V: Paris Descartes University)H-Index: 38
view all 23 authors...
Abstract Objective Atypical manifestations have been described in patients with ANCA-associated vasculitides (AAV), such as pachymeningitis, orbital mass or chronic periaortitis. Because these manifestations have been associated to the spectrum of IgG4-related disease (IgG4-RD), we hypothesized that both diseases could overlap. Methods We conducted a European retrospective multicenter observational study including patients fulfilling ACR and Chapel Hill criteria for AAV and IgG4-RD Comprehensive...
33 CitationsSource
#1Mikael Ebbo (AMU: Aix-Marseille University)H-Index: 18
#2Aurélie Grados (AMU: Aix-Marseille University)H-Index: 10
Last. Nicolas Schleinitz (AMU: Aix-Marseille University)H-Index: 28
view all 29 authors...
Objectives To assess efficacy and safety of rituximab (RTX) as induction therapy, maintenance of remission and treatment of relapses in a cohort of IgG4-related disease (IgG4-RD) patients. Methods Nationwide retrospective multicenter study of IgG4-RD patients treated with at least one course of RTX. Clinical, biological and radiological response, relapse rate and drug tolerance were analyzed. Kaplan-Meier curves were plotted and risk factors for relapse studied with a Cox regression model. Resul...
30 CitationsSource
#1Hisanori UmeharaH-Index: 37
#2Kazuichi Okazaki (Kansai Medical University)H-Index: 63
Last. Tsutomu Chiba (Kyoto University)H-Index: 76
view all 8 authors...
AbstractIgG4-related disease (IgG4-RD) is a fascinating clinical entity proposed by Japanese investigators, and includes a wide variety of diseases, formerly diagnosed as Mikulicz's disease (MD), autoimmune pancreatitis (AIP), interstitial nephritis, prostatitis, retroperitoneal fibrosis, etc. Although all clinicians in every field of medicine may encounter this new disease, a unifying diagnostic criterion has not been established. In 2011, the Japanese IgG4 team, organized by the Ministry of He...
39 CitationsSource
#1Hiroshi Sekiguchi (Mayo Clinic)H-Index: 15
#2Ryohei Horie (Mayo Clinic)H-Index: 7
Last. Jay H. Ryu (Mayo Clinic)H-Index: 74
view all 6 authors...
Objective To investigate clinical and pathologic aspects of IgG4-related disease (IgG4-RD) in non-Asian populations. Methods We conducted a retrospective review of the medical records of patients with IgG4-RD who presented to an academic medical center from January 1994 to September 2012. Results Among 166 patients identified, the median age at diagnosis was 61 years (interquartile range [IQR] 49–70 years), 75% were male, and 80% were white. The median number of organs involved was 2 (IQR 2–3). ...
22 CitationsSource
#1Yu Chen (Peking Union Medical College Hospital)H-Index: 4
#2J.Z. Zhao (Peking Union Medical College Hospital)H-Index: 2
Last. Fengchun Zhang (Peking Union Medical College Hospital)H-Index: 29
view all 9 authors...
Background: Immunoglobulin G4-related disease (IgG4-RD) is a newly recognized systemic disease that can involve multiple organs and various clinical phenotypes. The purpose of this study was to analyze different types of organ involvement in IgG4-RD patients in China.
20 CitationsSource
#1Zachary S. Wallace (Harvard University)H-Index: 18
#2Hamid Mattoo (MIT: Massachusetts Institute of Technology)H-Index: 16
Last. John H. Stone (Harvard University)H-Index: 70
view all 9 authors...
IgG4-related disease (IgG4-RD) is a relapsing-remitting condition responsible for fibroinflammatory lesions that can lead to organ damage and life-threatening complications at nearly any anatomical site. The duration of remission following treatment varies and predictors of relapse are unclear. The objectives of this study were to review our experience with rituximab as remission induction in IgG4-RD, to clarify the duration of efficacy and to identify predictors of flare following treatment.In ...
54 CitationsSource
#1Emma L. CulverH-Index: 16
#2Ross SadlerH-Index: 9
Last. Berne FerryH-Index: 25
view all 12 authors...
Elevated Serum IgG4 Levels in Diagnosis, Treatment Response, Organ Involvement, and Relapse in a Prospective IgG4-Related Disease UK Cohort
38 CitationsSource
#1Joohee LeeH-Index: 2
#2Seung Hyup HyunH-Index: 11
Last. Kyung-Han LeeH-Index: 36
view all 10 authors...
Abstract We investigated the capacity of F-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) to differentially diagnose immunoglobulin G4-related disease (IgG4-RD) in clinically suspected patients. Subjects were 94 clinically suspected patients who had tissue IgG4 staining (n = 85) or serum IgG4 greater than 135 mg/dL (n = 9) and underwent FDG PET/CT within 40 days. Clinical, serologic, pathological, and PET/CT findings were analyzed. Binary logistic regres...
9 CitationsSource
Cited By0
#1Josep DalmauH-Index: 88
#1Josep Dalmau (UCSF: University of California, San Francisco)
Last. Scott S. ZamvilH-Index: 52
view all 5 authors...
2019 has been a very good year for our journal. N2 was included in MEDLINE and in June received its first impact factor, a competitive 7.353. We have been fortunate to recruit Dr. Marinos Dalakas to our team of International Associate Editors. Dr. Dalakas is Professor of Neurology at the University of Athens (Greece) and Jefferson University (Philadelphia, PA). His remarkable knowledge on inflammatory and autoimmune neuromuscular diseases will be a great asset to the journal. These accomplishmen...